Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

More than 6,000 patients who underwent endoscopy at 18 NHS hospitals since the start of pandemic have been tested and none contracted COVID as a result of the procedure, a study involving clinicians from Oxford University Hospitals (OUH) NHS Foundation Trust has found.

Doctor holding endoscope

Clinicians hope the findings will persuade people that it is safe to attend their endoscopy appointments, which can be crucial in detecting cancer at an early stage. Detecting and treating cancer early is a key part of ongoing successful treatment.    

The findings coincide with a national campaign reminding people that safe cancer care is still available.  A recent survey showed that nearly half the public would delay or not seek medical help at all, with 22 per cent not wanting to burden the health service, and a similar number saying that fear of getting COVID-19 or passing it onto others was a major reason for not getting help.

The study, published in the international gastroenterology and hepatology journal, Gut, was conducted in 18 UK healthcare centres, which included tertiary and local settings serving a broad range of populations.

Data were collected from 6,208 patients undergoing endoscopy at the 18 centres between 30 April and 30 June 2020. Follow-up data on symptoms showed that there were no cases of COVID-19 detected – in the patients or staff - in the two weeks following the procedure.

The study was supported by the NIHR Oxford Biomedical Research Centre.

The full story is available on the Oxford University Hospitals (OUH) NHS Foundation Trust website

Similar stories

FOCUS4: a flagship trial in colorectal cancer

Professor Tim Maughan (Department of Oncology) outlines the flagship work of the FOCUS4 trials, whose results were presented last weekend at the European Society of Medical Oncology (ESMO) annual meeting

Oxford and Oracle partner to speed identification of COVID-19 variants

The fast spread of the highly infectious Delta variant underscores the need for faster identification of COVID-19 mutations. Uniting governments and medical communities in this challenge, the University of Oxford and Oracle’s Global Pathogen Analysis System (GPAS) is now being used by organizations on nearly every continent. Institutions using the platform include: the University of Montreal Hospital Centre Research Centre, the Institute of Public Health Research of Chile, the Oxford University Clinical Research Unit in Vietnam, the Institute of Clinical Pathology and Medical Research – New South Wales Pathology, and Oxford Nanopore Technologies. GPAS is also now part of the Public Health England New Variant Assessment Platform.

Vaccinated groups at highest risk of Covid-19 hospitalisation and death identified using new QCovid tool

Researchers from the University of Oxford have today reported on findings on the vaccinated people who are at greatest risk from severe Covid-19 leading to hospitalisation or death from 14 days post the second dose vaccination, when substantial immunity should be expected.

Com-COV vaccine mix-and-match study expands to 12-to-16-year-olds

Researchers running the University of Oxford-led Com-COV programme have launched a new study of COVID-19 vaccination schedules in young people aged 12 to 16.

Researchers develop machine learning algorithm to diagnose deep vein thrombosis

A team of researchers are developing the use of an artificial intelligence (AI) algorithm with the aim of diagnosing deep vein thrombosis (DVT) more quickly and as effectively as traditional radiologist-interpreted diagnostic scans, potentially cutting down long patient waiting lists and avoiding patients unnecessarily receiving drugs to treat DVT when they don’t have it.